All In Biotech

Drug Trial Radar · NCT06418061

Study of IBI3005 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors

A Multicenter, Open-label, Phase Ia/Ib Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of IBI3005 in Subjects With Advanced Malignant Solid Tumors

Last checked: Nov 19, 2026Latest source record: Jan 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

198

Planned (sponsor's estimate)

Start

Jan 8, 2025

Primary completion

Jun 30, 2027

Study completion Dec 31, 2027

Sponsor

Sponsor type
Industry
First posted
May 16, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main purpose of this study is to evaluate the safety and tolerability of IBI3005 and to determine the maximum tolerated dose (MTD) and the recommended Phase 2 Dose (RP2D) of IBI3005.

Conditions

  • Unresectable
  • Locally Advanced or Metastatic Solid Tumors

Interventions

  • IBI3005Drug

    Bispecific Monoclonal Antibody-Camptothecin Derivative Conjugate for Injection (R \& D code: IBI3005)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Numbers of subjects with adverse eventsTime frame: Up to 3 years
  2. Number of subjects with clinically significant changes in physical examination resultsTime frame: Up to 3 years
  3. Number of subjects with clinically significant changes in vital signsTime frame: Up to 3 years
  4. Dose limiting toxicities (DLTs)Time frame: Up to 4 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shandong Cancer Hospital & Institute

    Jinan, Shandong, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.